- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07940842
AI Voice Calls Versus Text and Email Reminders for Questionnaire Response After Shoulder Arthroplasty (VOICE-REACH)
Proactive Conversational Artificial Intelligence Calls Versus Digital Reminders to Collect Patient-Reported Outcomes After Shoulder Arthroplasty: A Randomized Study Within a Multicenter Cohort
After shoulder replacement surgery, surgeons send questionnaires to their patients to learn how they are doing (pain, shoulder function, satisfaction). Many patients do not answer. This study tests the best way to obtain these answers.
The study is nested in a multicenter study of pain after shoulder arthroplasty conducted in four French centers (host study RetroPAinRSACAll, supported by Ramsay Santé). The clinical results of the host study are not the subject of this registration: this study evaluates only the method used to collect the information.
All patients first receive an email invitation (when an email address is available) and, the next day, a text message (SMS) with a personal link to the questionnaire and a phone number to answer at any time by talking with an automated voice assistant. Patients who have not answered two days after the first contact are randomly assigned to one of two follow-up strategies: (1) further digital reminders (SMS on day 3 and day 5, email on day 7), or (2) up to three phone calls from a conversational artificial intelligence (AI) voice agent on days 3, 5 and 7, which asks the same questions orally. In both groups, patients can answer at any time online or by calling the voice assistant, and contacts stop as soon as the questionnaire is completed or the patient refuses.
The main outcome is the proportion of patients who complete the questionnaire within 14 days of the first contact.
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Design. VOICE-REACH is a pragmatic, multicenter, individually randomized, two-arm, open-label superiority study within a trial (SWAT). It is embedded in the host study RetroPAinRSACAll (persistent pain after shoulder arthroplasty, four French shoulder surgery centers, favorable opinion of the Ramsay Santé scientific committee, reference COS-RGDS-2026-07-008). All patients of the host cohort are contacted through the DeepCall platform on behalf of their surgeon to complete the host study questionnaire (operation details, warning signs, pain screening and characterization, rehabilitation and function including the Subjective Shoulder Value, opinion on the operation and on the contact). The comparison concerns the follow-up strategy only: the questionnaire is the same in both arms and the same on the web and by voice.
Common phase (all participants). Day 0: email invitation with a personal questionnaire link, sent when an email address is available. Day 1: SMS with the same link, the phone number of the AI voice agent (available 24 hours a day for inbound calls) and an opt-out option (reply NO). Patients are contacted in successive waves of up to 450 patients, one day apart, to respect operator sending limits; all study days are counted from each participant's own day 0.
Randomization. On day 2, participants who have not completed the questionnaire and have not refused are randomized 1:1 by the platform, using a computer-generated permuted block sequence (blocks of 4) stratified by center. Participants who completed the questionnaire before day 2 are not randomized and are described separately.
Arm A, digital reminders: SMS reminders on day 3 and day 5 and an email reminder on day 7 (when an email address is available).
Arm B, proactive AI calls: outbound calls from the AI voice agent on day 3, day 5 and day 7 (up to three attempts). The agent calls on behalf of the surgeon's team and asks the questionnaire orally; answers are extracted into the same structured fields as the web form.
In both arms, the web link and the inbound voice line remain available throughout, and all scheduled contacts stop as soon as the questionnaire is completed, the patient refuses, or the patient is identified as deceased. Warning signs reported by patients are flagged to the surgical team for review; the AI agent does not give medical advice.
Analysis. The primary analysis is intention to treat among all randomized participants: proportion with a completed questionnaire by day 14, risk difference (Arm B minus Arm A) with 95% confidence interval, adjusted for center and email availability. Participants without a completed questionnaire by day 14 are counted as non-completers; no answer is imputed. Secondary analyses describe the yield of the common phase, time to completion, completion channel, partial responses, refusals, number of contacts and cost per completed questionnaire, acceptability of the contact mode among responders, representativeness of responders, and the accuracy of voice-captured answers.
Registration timing. The common pre-randomization outreach started on 9 November 2026. This record was created on 10 November 2026, before the first randomization (day 2 of the first wave, 11 November 2026).
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Jules Descamps, MD
- Telefoonnummer: 0698270789
- E-mail: dr.jdescamps@gmail.com
Studie Locaties
-
-
-
Caen, Frankrijk, 14000
- Werving
- Hôpital Privé Saint-Martin
-
Hoofdonderzoeker:
- Franck Dordain, MD
-
Lyon, Frankrijk, 69008
- Werving
- Centre Orthopédique Santy, Hôpital Privé Jean Mermoz
-
Hoofdonderzoeker:
- Arnaud Godenèche, MD
-
Paris, Frankrijk, 75019
- Werving
- Clinique des Maussins-Nollet
-
Hoofdonderzoeker:
- Geoffroy Nourissat, MD, PhD
-
Strasbourg, Frankrijk, 67000
- Werving
- Clinique de l'Orangerie
-
Hoofdonderzoeker:
- Maxime Antoni, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age 18 years or older
- Shoulder arthroplasty (reverse, anatomic, humeral head replacement or revision arthroplasty) performed at one of the four participating centers and listed in the host study cohort
- At least one telephone number available (an email address is not required)
Additional criteria for randomization (day 2):
* Questionnaire not completed and no refusal at the day-2 cutoff
Exclusion Criteria:
- Death identified before the first contact (cross-check with the French national death registry, INSEE)
- Duplicate record
- Refusal of contact
- Questionnaire already completed before day 2 (excluded from randomization only, described separately)
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: Digital Reminders
Common phase: email invitation on day 0 (if an email address is available) and SMS invitation on day 1 with the questionnaire link and the AI voice agent phone number. After randomization on day 2: SMS reminder on day 3, SMS reminder on day 5 and email reminder on day 7 (if an email address is available). Participants can answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal. |
Standardized reminder messages sent by the DeepCall platform on behalf of the surgeon: SMS on day 3 and day 5 and email on day 7 (if an email address is available), each with the personal questionnaire link, the AI voice agent phone number and an opt-out option. |
|
Experimenteel: Proactive AI Voice Calls
Same common phase (email on day 0 if available, SMS on day 1). After randomization on day 2: up to three outbound calls from the conversational AI voice agent on day 3, day 5 and day 7, during which the same questionnaire is asked orally. Participants can also answer at any time by web link or by calling the AI voice agent. Contacts stop at completion or refusal. |
Outbound telephone calls placed by a conversational AI voice agent (DeepCall platform) on day 3, day 5 and day 7, up to three attempts. The agent calls on behalf of the surgeon's team, conducts the same questionnaire orally and records the answers in the same structured fields as the web form.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Questionnaire Completion by Day 14 Among Randomized Participants
Tijdsspanne: From day 0 (first contact) to day 14
|
Proportion of randomized participants with a completed questionnaire within 14 days of their first contact (day 0), whatever the channel used (web link, inbound call or outbound AI call). A questionnaire is complete when it was submitted on the web or when all required items were answered during a voice interview. Participants without a completed questionnaire at the day-14 cutoff are counted as non-completers. Compared between arms (proactive AI voice calls minus digital reminders). |
From day 0 (first contact) to day 14
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Questionnaire Completion by Day 7 Among Randomized Participants
Tijdsspanne: From day 0 to day 7
|
Proportion of randomized participants with a completed questionnaire by day 7, whatever the channel used. |
From day 0 to day 7
|
|
Time to Questionnaire Completion
Tijdsspanne: From day 2 to day 14
|
Time in hours from randomization (day 2) to questionnaire completion among randomized participants; participants without a completed questionnaire are censored at day 14. |
From day 2 to day 14
|
|
Questionnaire Completion Before Randomization
Tijdsspanne: From day 0 to day 2
|
Proportion of all enrolled participants who completed the questionnaire after the common email (day 0) and SMS (day 1) invitations, before the day-2 randomization. |
From day 0 to day 2
|
|
Questionnaire Completion by Day 14 in All Enrolled Participants
Tijdsspanne: From day 0 to day 14
|
Proportion of all enrolled participants, randomized or not, with a completed questionnaire by day 14. |
From day 0 to day 14
|
|
Partial Questionnaire Response
Tijdsspanne: From day 0 to day 14
|
Proportion of randomized participants who answered at least one question without completing the questionnaire by day 14. |
From day 0 to day 14
|
|
Completion Channel
Tijdsspanne: From day 0 to day 14
|
Distribution of completed questionnaires by channel (web link, inbound call to the voice agent, outbound AI call), by arm. |
From day 0 to day 14
|
|
Refusal of Contact
Tijdsspanne: From day 2 to day 14
|
Proportion of randomized participants who explicitly refused further contact (SMS reply, email refusal link or refusal during a call). |
From day 2 to day 14
|
|
Number of Contacts per Completed Questionnaire
Tijdsspanne: From day 0 to day 14
|
Number of emails, SMS and outbound calls sent or attempted, divided by the number of completed questionnaires, by arm. |
From day 0 to day 14
|
|
Direct Cost per Completed Questionnaire
Tijdsspanne: From day 0 to day 14
|
Direct costs of messaging, telephony and AI processing (euros) divided by the number of completed questionnaires, by arm, and incremental cost per additional completed questionnaire. |
From day 0 to day 14
|
|
Satisfaction With the Mode of Contact
Tijdsspanne: From day 0 to day 14
|
Among participants who completed the questionnaire: satisfaction with the way they were contacted, rated on a 5-level scale from very satisfied to very dissatisfied. |
From day 0 to day 14
|
|
Perceived Number of Contacts
Tijdsspanne: From day 0 to day 14
|
Among participants who completed the questionnaire: perceived number of contacts (too many, appropriate, too few). |
From day 0 to day 14
|
|
Preferred Contact Mode for Future Follow-up
Tijdsspanne: From day 0 to day 14
|
Among participants who completed the questionnaire: preferred mode of contact for future follow-up questionnaires (categorical). |
From day 0 to day 14
|
|
Characteristics of Responders Versus Non-Responders
Tijdsspanne: Day 14
|
Age, center, type of arthroplasty and time since surgery (when available in the host cohort) compared between participants who completed the questionnaire and those who did not, by arm (standardized differences). |
Day 14
|
|
Agreement Between Voice-Captured Answers and Human Review
Tijdsspanne: From day 0 to day 14
|
In a random sample of completed voice interviews, agreement between the answers extracted by the AI agent and those coded by a reviewer listening to the recording, blinded to the extracted values (percentage agreement, kappa or intraclass correlation coefficient). |
From day 0 to day 14
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Delivery of Email and SMS Invitations
Tijdsspanne: From day 0 to day 7
|
Proportion of emails and SMS delivered, bounced or filtered by the operator, as reported by the sending providers. |
From day 0 to day 7
|
|
Outbound Call Outcomes
Tijdsspanne: From day 3 to day 7
|
Distribution of outbound AI call outcomes (answered, voicemail, no answer, filtered, failed) and call duration in the proactive AI voice calls arm. |
From day 3 to day 7
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Jules Descamps, MD, MSc, Hopital Lariboisière
- Studie stoel: Geoffroy Nourissat, MD, PhD, Clinique des Maussins-Nollet, Ramsay Santé
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- VOICE-REACH
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Identifiable data, call recordings and transcripts will not be shared. Aggregated results will be published.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .